Article ID Journal Published Year Pages File Type
1920746 Parkinsonism & Related Disorders 2011 7 Pages PDF
Abstract

Overactivity of glutamatergic transmission has been implicated in Parkinson’s disease (PD) and levodopa (l-Dopa)-induced dyskinesias. Striatal metabotropic glutamate receptors type 5 (mGluR5) are abundant and provide specific targets to modulate glutamatergic activity. This study investigated the acute effects of the novel mGluR5 antagonist AFQ056 on motor behavior in l-Dopa-treated monkeys with a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) lesion to model PD. Six Macaca fascicularis MPTP monkeys were treated repeatedly with l-Dopa; this treatment increased their locomotion and reduced their parkinsonian scores, but also induced dyskinesias. When AFQ056 (doses of 5, 25, 125 or 250 mg/kg) was administered one hour prior to a high dose of l-Dopa, the antiparkinsonian activity of l-Dopa was maintained as measured with locomotion and antiparkinsonian scores, whereas dyskinesias were significantly reduced at 25, 125 and 250 mg/kg AFQ056 for peak dyskinesia score and at 125 and 250 mg/kg for the 1 h peak period of dyskinesia score. Administration of AFQ056 one hour before l-Dopa led to peak or elevated plasma AFQ056 concentrations occurring close to l-Dopa peak-dose dyskinesias. We next investigated AFQ056 25 mg/kg combined with a low dose of l-Dopa. The antiparkinsonian activity of l-Dopa was increased as measured with locomotion, while dyskinesias remained low at these doses. Our results show a beneficial motor effect of AFQ056 with l-Dopa in MPTP monkeys. This supports the therapeutic use of an mGluR5 antagonist to restore normal glutamatergic neurotransmission in PD and decrease dyskinesias.

Related Topics
Life Sciences Biochemistry, Genetics and Molecular Biology Ageing
Authors
, , , , , , , , , ,